- Home
- CFBK vs PBYI Comparison
CFBK vs PBYI Comparison
Compare CFBK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- PBYI
- Stock Information
- Founded
- CFBK 1892
- PBYI 2010
- Country
- CFBK United States
- PBYI United States
- Employees
- CFBK N/A
- PBYI N/A
- Industry
- CFBK Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CFBK Finance
- PBYI Health Care
- Exchange
- CFBK Nasdaq
- PBYI Nasdaq
- Market Cap
- CFBK 127.9M
- PBYI 152.4M
- IPO Year
- CFBK 1998
- PBYI N/A
- Fundamental
- Price
- CFBK $23.94
- PBYI $3.28
- Analyst Decision
- CFBK Buy
- PBYI Strong Buy
- Analyst Count
- CFBK 1
- PBYI 1
- Target Price
- CFBK $29.00
- PBYI $7.00
- AVG Volume (30 Days)
- CFBK 22.9K
- PBYI 375.3K
- Earning Date
- CFBK 05-06-2025
- PBYI 05-08-2025
- Dividend Yield
- CFBK 1.17%
- PBYI N/A
- EPS Growth
- CFBK N/A
- PBYI 143.51
- EPS
- CFBK 2.28
- PBYI 0.77
- Revenue
- CFBK $47,663,000.00
- PBYI $232,709,000.00
- Revenue This Year
- CFBK N/A
- PBYI N/A
- Revenue Next Year
- CFBK N/A
- PBYI N/A
- P/E Ratio
- CFBK $10.49
- PBYI $4.25
- Revenue Growth
- CFBK 1.22
- PBYI 2.68
- 52 Week Low
- CFBK $16.92
- PBYI $2.23
- 52 Week High
- CFBK $31.17
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- CFBK 61.06
- PBYI 52.36
- Support Level
- CFBK $23.61
- PBYI $3.14
- Resistance Level
- CFBK $24.25
- PBYI $3.45
- Average True Range (ATR)
- CFBK 0.29
- PBYI 0.19
- MACD
- CFBK -0.07
- PBYI 0.01
- Stochastic Oscillator
- CFBK 48.51
- PBYI 51.19
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.